- Research article
- Open Access
Pro-protein convertases control the maturation and processing of the iron-regulatory protein, RGMc/hemojuvelin
© Kuninger et al; licensee BioMed Central Ltd. 2008
- Received: 22 December 2007
- Accepted: 02 April 2008
- Published: 02 April 2008
Repulsive guidance molecule c (RGMc or hemojuvelin), a glycosylphosphatidylinositol-linked glycoprotein expressed in liver and striated muscle, plays a central role in systemic iron balance. Inactivating mutations in the RGMc gene cause juvenile hemochromatosis (JH), a rapidly progressing iron storage disorder with severe systemic manifestations. RGMc undergoes complex biosynthetic steps leading to membrane-bound and soluble forms of the protein, including both 50 and 40 kDa single-chain species.
We now show that pro-protein convertases (PC) are responsible for conversion of 50 kDa RGMc to a 40 kDa protein with a truncated COOH-terminus. Unlike related molecules RGMa and RGMb, RGMc encodes a conserved PC recognition and cleavage site, and JH-associated RGMc frame-shift mutants undergo COOH-terminal cleavage only if this site is present. A cell-impermeable peptide PC inhibitor blocks the appearance of 40 kDa RGMc in extra-cellular fluid, as does an engineered mutation in the conserved PC recognition sequence, while the PC furin cleaves 50 kDa RGMc in vitro into a 40 kDa molecule with an intact NH2-terminus. Iron loading reduces release of RGMc from the cell membrane, and diminishes accumulation of the 40 kDa species in cell culture medium.
Our results define a role for PCs in the maturation of RGMc that may have implications for the physiological actions of this critical iron-regulatory protein.
- Iron Homeostasis
- Hep3B Cell
- Iron Loading
- Ferric Ammonium Citrate
Iron is an essential element required for many cellular processes, including energy metabolism, oxygen transport, and respiration . Iron homeostasis is tightly regulated, and there are major health consequences linked to both its deficiency and excess  Normal iron homeostasis is disrupted in hemochromatosis, a heterogenous hereditary disorder of iron overload. Juvenile hemochromatosis (JH) is a rapidly progressive form of this disease with severe systemic consequences if untreated . Many patients with JH have mutations in the HJV gene, which encodes hemojuvelin [4–7], and mice lacking hjv develop an iron-overload phenotype [8, 9]. Hemojuvelin is identical to RGMc, and with RGMa and RGMb, comprise the repulsive guidance molecule (RGM) family [4, 10, 11]. RGMa and b are produced primarily in the central nervous system [11, 12], and play roles in neuronal survival and patterning [11, 12], while RGMc is synthesized in liver and striated muscle [10, 11, 13, 14]. All three RGM genes encode glycosylphosphatidylinositol-anchored and soluble glycoproteins. For RGMc, these consist of single-chain and heterodimeric membrane-linked molecules, and soluble 50 and 40 kDa single-chain proteins that arise from an incompletely defined biosynthetic and processing pathway [14–17].
The mechanisms by which RGMc participates in systemic iron balance are unknown. The liver-derived hormone, hepcidin, is an essential regulator of iron homeostasis that acts by controlling intestinal iron absorption and recovery from macrophages . Hepcidin binds to the membrane iron transporter, ferroportin, leading to its degradation . In hemochromatosis, hepcidin levels are low, and dietary iron uptake is excessive . Recent studies have suggested that membrane-associated RGMc increases hepcidin gene expression in the liver by collaboration with signaling pathways activated by bone morphogenic proteins (BMP) 2 and 4 [18, 19], and thus acts to prevent iron import. By contrast, soluble RGMc may inhibit hepcidin synthesis [15, 20]. RGMc also may promote iron uptake into cells , but biochemical mechanisms have not been defined.
Here we demonstrate a role for pro-protein convertases (PC) in the biogenesis of RGMc, and in their regulation by iron. Through biochemical and cell-based approaches we show that PCs cleave full-length 50 kDa RGMc at an evolutionarily conserved recognition site into a 40 kDa soluble species truncated at its COOH-terminus. Both 50 and 40 kDa RGMc are found in the blood of humans and mice, and in extra-cellular fluid of cultured cells. The relative ratio and overall abundance of both RGMc species appears to be altered by cellular iron levels, with iron loading leading to a decline in soluble RGMc, but an increase in the 50 kDa isoform and in the amount of single chain RGMc retained on the cell membrane. Thus our results define potential interactions between PCs and iron to control the expression of a critical iron-regulatory protein.
All cells were incubated at 37°C in humidified air and 5% CO2. The following established cell lines were used. Murine C3H10T1/2 cells (ATCC #CCL-226, Manassas, VA, USA) and C2 myoblasts  were grown on gelatin-coated dishes in DMEM (Mediatech-Cellgro, Herndon, VA, USA) plus 10% heat-inactivated fetal calf serum (FCS, Hyclone, Logan, UT, USA). C3H10T1/2 cells were infected at ~50% of confluent density with a recombinant adenovirus encoding MyoD, as described , and muscle differentiation-promoting medium (DMEM and 2% horse serum (Hyclone)) was added 24 h later. C2 myoblasts were incubated at confluent cell density in muscle differentiation-promoting medium, as described . Cos-7 (ATCC #CRL-1651) and Hep3B cells (ATCC #HB-8064) were grown in DMEM and 10% FCS. Ferric ammonium choride or the iron chelator deferoxamine (Sigma, St. Louis, MO, USA) was added to medium for 24 h.
Ad-MyoD, Ad-tTA (tetracycline transactivator protein), Ad-HA-RGMc, and Ad-HA-RGMcΔGPI have been described [14, 21]. At 18 h after viral infection, new medium was added (DMEM and 2% horse serum) containing the cell-impermeable pro-protein convertase inhibitor, decanoyl-Arg-Val-Lys-Arg-chloromethyl-ketone [10 μM] (RVKR, Alexis Biochemicals, San Diego, CA, USA) or DMSO. Cells and medium were harvested over the next 24 h. Hep3B cells were infected at ~50% confluent density with Ad-HA-RGMc or Ad-HA-RGMcΔGPI, and Ad-tTA, and treated similarly.
Expression of RGMc mutants
We previously cloned a mouse RGMc cDNA from skeletal muscle cells . The following codon changes were introduced into the cDNA by site-directed mutagenesis (Stratagene, San Diego, CA, USA): R318G, R321A, R324A. Mouse RGMc truncation mutants were made by PCR by replacing codons after R378, C354, S321 and Q305 with a 6× His epitope tag and stop codon. These alterations correspond respectively to human JH-associated frame-shift mutations R385X, C361fsX366, S328fsX337 and Q312X [4–7]. DNA sequencing was used to confirm all nucleotide changes, and the regions with mutations were subcloned into HA-RGMc in pcDNA3 . Transient transfections were performed using 2 μg of DNA/35 mm dish, and RVKR or DMSO were added 18 h later. Cells and medium were harvested after an additional 24 h.
Conditions for preparation of whole cell protein lysates and culture medium, SDS-PAGE, and immunoblotting have been described . Primary antibodies included: mouse RGMc (1:750 dilution) , HA (Covance, Denver, PA, USA; 1:4000), α-tubulin (Sigma, 1:4000), His (Abcam, Cambridge, MA, USA; 1:1000), and pan-cadherin (Cell Signaling, Danvers, MA, USA; 1:1000). Secondary antibodies included Alexa 680-conjugated anti-mouse IgG (Molecular Probes, Eugene, OR, USA; 1:4000) and IRD 800-conjugated anti-rabbit IgG (Rockland, Gilbertsville, PA, USA; 1:4000).
Purification of RGMc
An antibody affinity column was prepared by coupling 1.5 mg of antigen-purified rabbit anti-RGMc IgG to CNBr-activated Sephadex 4B (Amersham-Pharmacia, Piscataway, NJ, USA). Serum was obtained from two healthy humans (ages 25 and 35), and two male mice (age 10 and 12 weeks). Mouse or human serum (0.5 ml) or conditioned culture medium (1 ml) was diluted into 10 mM TrisHCl, pH 7.4, 0.05% Tween-20, and protease inhibitors (Roche, Indianapolis, IN, USA). Samples were pre-cleared with protein-A agarose (Sigma) for 4 h at 4°C, then incubated with affinity resin for 16 h at 4°C. Following washes (10 column volumes of 10 mM TrisHCl, pH 7.4, 0.05% Tween-20), proteins were eluted with 0.5 ml of 100 mM glycine, pH 2.5, and neutralized with 1 M TrisHCl, pH 8.0. A total of 50 μl was used for detection by SDS-PAGE and immunoblotting .
Cell-surface biotin labeling
Monolayer cultures were incubated with EZ-link sulfo-NHS-biotin (1 mg/ml, Pierce, Rockford, IL) for 30 min at 4°C, followed by incubation in medium ± RVKR, 'pull-down' of protein extracts or culture medium with streptavidin-agarose, and SDS-PAGE and immunoblotting .
Incubation of RGMc with cells or recombinant furin
Conditioned medium from cells expressing RGMc plus RVKR was dialyzed to remove inhibitor. Aliquots (200 μl) were added to Hep3B cells plus fresh RVKR or DMSO for 24 h at 37°C, followed by SDS-PAGE and immunoblotting. Dialyzed medium (25 μl) was incubated with 10 U recombinant human furin for 4 h at 30°C in 100 mM Hepes, pH 7.4, 1 mM CaCl2, and 0.5% Triton-X100, followed by SDS-PAGE and immunoblotting.
A pro-protein convertase inhibitor prevents accumulation of soluble 40 kDa RGMc
RGMc is produced by hepatocytes and striated muscle [8, 13, 15]. We have detected RGMc on muscle cell membranes, and have found that proteins of ~50, 35, and 20 kDa are released into the extracellular fluid after incubation with bacterial PI-PLC , illustrating that RGMc is attached to the membrane by a GPI linkage. The two smaller protein bands comprise a disulfide-linked heterodimer, while the larger species is full-length single-chain RGMc . Similar results have been observed for RGMc over-expressed in cell lines [14–16]. RGMc also accumulates in medium conditioned by muscle cells as 50 and 40 kDa single-chain proteins , suggesting either direct secretion or release from the plasma membrane.
Mapping the location of PC cleavage by analysis of JH-associated RGMc frame-shift mutations
Altered processing of newly synthesized RGMc in the presence of PC inhibitor
We used cell surface-labeling experiments to study the impact of PC inhibition on acute release of membrane-linked RGMc into the medium. In Hep3B cells expressing HA-RGMc, membrane proteins were labeled for 30 min with cell-impermeable biotin cross-linker followed by addition of RVKR or vehicle. Release of RGMc from the cell surface was monitored by immunoblotting after streptavidin pull-down of culture medium. Biotinylated 40 and 50 kDa RGMc were detected in medium at 2 and 4 h after labeling, and more 50 kDa RGMc was seen with RVKR, although the total amount of RGMc declined by ~35% (Fig. 3B). These results show that both 50 and 40 kDa soluble RGMc species derive from cell-associated 50 kDa RGMc, and demonstrate that inhibition of PC activity diminishes but does not prevent release of membrane-linked RGMc into extracellular fluid.
Furin cleaves 50 kDa RGMc to produce a 40 kDa species
PC activity may be found in intracellular compartments, at the membrane, and in the extra-cellular milieu . To determine where cleavage of 50 kDa RGMc may occur, conditioned medium from Cos-7 cells expressing HA-RGMc was collected in the presence of RVKR, and after dialysis to remove the inhibitor, added to Hep3B cells. Following incubation for 24 h, significant conversion to 40 kDa RGMc was observed, but was not seen when RVKR was added (Fig. 4B), indicating that these cells produce PCs that act extra-cellularly.
The R-N-R-R sequence in RGMc (Fig. 1A) represents an optimal furin site . In agreement with this idea, incubation of 50 kDa RGMc with recombinant furin in vitro led to its efficient cleavage into a 40 kDa species with an intact NH2-terminus, as shown by detection with both anti-HA and anti-RGMc antibodies (Fig. 4C). Thus by several criteria, 50 kDa RGMc is a PC substrate.
Effects of iron on processing of RGMc and its release from the cell membrane
In this manuscript we show that RGMc accumulates in extra-cellular fluid of cultured cells and in mouse and human serum as 50 and 40 kDa protein species (Fig. 1). As is evident from cell-surface binding experiments, both molecules originate from cell-membrane-associated GPI-linked single-chain RGMc (Fig. 3), and the 40 kDa isoform is derived from the 50 kDa species by targeted proteolysis mediated by PCs such as furin (Fig. 4), with cleavage occurring at a site that is highly conserved among RGMc orthologues, but is absent in the paralogues, RGMa and RGMb (Fig. 1). Taken together, our results define a key role for PCs in the regulation of RGMc that has implications for the physiological effects of this critical iron-regulatory protein.
Are there specific biological effects of different RGMc protein species?
The biological actions of RGMc are not yet fully defined. A role for RGMc in iron homeostasis is postulated based on the discovery of multiple mutations in the HJV gene in patients with JH [4–7], and on the iron overload phenotype in mice lacking hjv [8, 9]. Loss of RGMc is associated with severe reduction in hepcidin [4, 8, 9], a critical negative regulator of iron absorption, placing RGMc upstream in a pathway controlling hepcidin production in the liver . Cell-associated RGMc can enhance effects of BMPs to increase hepcidin gene expression, potentially through direct binding to BMP2 and 4 [18, 19], but it is not known if these actions are mediated by single-chain or heterodimeric RGMc. In contrast, soluble RGMc appears to inhibit production of hepcidin mRNA [15, 20]. It is not known if 50 or 40 kDa soluble RGMc proteins preferentially bind to BMPs, or if they have other actions, although a recent report showed that soluble 40 kDa RGMc blunted stimulation of hepcidin gene expression by BMP2 in cultured cells . This latter observation indicates that PC activity may influence the biological actions of RGMc.
Does iron regulate RGMc?
Serum levels of RGMc were shown to transiently increase in acutely iron-deficent rats , and incubation of cultured cells with holo-transferrin for 24 – 48 h caused a reduction in RGMc in the medium [15, 24]. This latter effect was attributed to a decline in the extent of shedding of membrane-linked RGMc . We find in agreement with these results that iron loading increased the amount of single-chain RGMc on the cell membrane, and caused a commensurate decline in accumulation of 40 kDa RGMc in the extra-cellular fluid, while the abundance of the soluble 50 kDa species increased. Additional work will be needed to define the mechanisms by which iron alters the biogenesis and processing of RGMc, although as suggested by Silvestri et al , one possibility may be through control of furin production.
RGMc, pro-protein convertases, and iron metabolism
We thank Dr. Ujwal Shinde for advice and for recombinant furin. These studies were supported in part by NIH grants RO1 DK42748 (P. R.) and F32 DK076348 (R. K-H.).
- Hentze MW, Muckenthaler MU, Andrews NC: Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004, 117: 285-297. 10.1016/S0092-8674(04)00343-5.View ArticlePubMedGoogle Scholar
- Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004, 306: 2090-2093. 10.1126/science.1104742.View ArticlePubMedGoogle Scholar
- Beutler E: Hemochromatosis: genetics and pathophysiology. Annu Rev Med. 2006, 57: 331-347. 10.1146/annurev.med.57.121304.131310.View ArticlePubMedGoogle Scholar
- Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube MP, Andres L, MacFarlane J, Sakellaropoulos N, Politou M, Nemeth E, Thompson J, Risler JK, Zaborowska C, Babakaiff R, Radomski CC, Pape TD, Davidas O, Christakis J, Brissot P, Lockitch G, Ganz T, Hayden MR, Goldberg YP: Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004, 36: 77-82. 10.1038/ng1274.View ArticlePubMedGoogle Scholar
- Lanzara C, Roetto A, Daraio F, Rivard S, Ficarella R, Simard H, Cox TM, Cazzola M, Piperno A, Gimenez-Roqueplo AP, Grammatico P, Volinia S, Gasparini P, Camaschella C: Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood. 2004, 103: 4317-4321. 10.1182/blood-2004-01-0192.View ArticlePubMedGoogle Scholar
- Gehrke SG, Pietrangelo A, Kascak M, Braner A, Eisold M, Kulaksiz H, Herrmann T, Hebling U, Bents K, Gugler R, Stremmel W: HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet. 2005, 67: 425-428. 10.1111/j.1399-0004.2005.00413.x.View ArticlePubMedGoogle Scholar
- Koyama C, Hayashi H, Wakusawa S, Ueno T, Yano M, Katano Y, Goto H, Kidokoro R: Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J Hepatol. 2005, 43: 740-742. 10.1016/j.jhep.2005.06.024.View ArticlePubMedGoogle Scholar
- Niederkofler V, Salie R, Arber S: Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest. 2005, 115: 2180-2186. 10.1172/JCI25683.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC: A mouse model of juvenile hemochromatosis. J Clin Invest. 2005, 115: 2187-2191. 10.1172/JCI25049.PubMed CentralView ArticlePubMedGoogle Scholar
- Schmidtmer J, Engelkamp D: Isolation and expression pattern of three mouse homologues of chick Rgm. Gene Expr Patterns. 2004, 4: 105-110. 10.1016/S1567-133X(03)00144-3.View ArticlePubMedGoogle Scholar
- Niederkofler V, Salie R, Sigrist M, Arber S: Repulsive guidance molecule (RGM) gene function is required for neural tube closure but not retinal topography in the mouse visual system. J Neurosci. 2004, 24: 808-818. 10.1523/JNEUROSCI.4610-03.2004.View ArticlePubMedGoogle Scholar
- Samad TA, Srinivasan A, Karchewski LA, Jeong SJ, Campagna JA, Ji RR, Fabrizio DA, Zhang Y, Lin HY, Bell E, Woolf CJ: DRAGON: a member of the repulsive guidance molecule-related family of neuronal- and muscle-expressed membrane proteins is regulated by DRG11 and has neuronal adhesive properties. J Neurosci. 2004, 24: 2027-2036. 10.1523/JNEUROSCI.4115-03.2004.View ArticlePubMedGoogle Scholar
- Kuninger D, Kuzmickas R, Peng B, Pintar JE, Rotwein P: Gene discovery by microarray: identification of novel genes induced during growth factor-mediated muscle cell survival and differentiation. Genomics. 2004, 84: 876-889. 10.1016/j.ygeno.2004.07.013.View ArticlePubMedGoogle Scholar
- Kuninger D, Kuns-Hashimoto R, Kuzmickas R, Rotwein P: Complex biosynthesis of the muscle-enriched iron regulator RGMc. J Cell Sci. 2006, 119: 3273-3283. 10.1242/jcs.03074.View ArticlePubMedGoogle Scholar
- Lin L, Goldberg YP, Ganz T: Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood. 2005, 106: 2884-2889. 10.1182/blood-2005-05-1845.View ArticlePubMedGoogle Scholar
- Zhang AS, West APJ, Wyman AE, Bjorkman PJ, Enns CA: Interaction of hemojuvelin with neogenin results in iron accumulation in human embryonic kidney 293 cells. J Biol Chem. 2005, 280: 33885-33894. 10.1074/jbc.M506207200.View ArticlePubMedGoogle Scholar
- Silvestri L, Pagani A, Fazi C, Gerardi G, Levi S, Arosio P, Camaschella C: Defective targeting of hemojuvelin to plasma membrane is a common pathogenetic mechanism in juvenile hemochromatosis. Blood. 2007, 109: 4503-4510. 10.1182/blood-2006-08-041004.View ArticlePubMedGoogle Scholar
- Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC, Lin HY: Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006, 38: 531-539. 10.1038/ng1777.View ArticlePubMedGoogle Scholar
- Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY: Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007, 117: 1933-1939. 10.1172/JCI31342.PubMed CentralView ArticlePubMedGoogle Scholar
- Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T: Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood. 2007, 110: 2182-2189. 10.1182/blood-2007-04-087593.PubMed CentralView ArticlePubMedGoogle Scholar
- Wilson EM, Hsieh MM, Rotwein P: Autocrine growth factor signaling by insulin-like growth factor-II mediates MyoD-stimulated myocyte maturation. J Biol Chem. 2003, 278: 41109-41113. 10.1074/jbc.C300299200.View ArticlePubMedGoogle Scholar
- Seidah NG, Chretien M: Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res. 1999, 848: 45-62. 10.1016/S0006-8993(99)01909-5.View ArticlePubMedGoogle Scholar
- Thomas G: Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 2002, 3: 753-766. 10.1038/nrm934.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang AS, Anderson SA, Meyers KR, Hernandez C, Eisenstein RS, Enns CA: Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem. 2007, 282: 12547-12556. 10.1074/jbc.M608788200.View ArticlePubMedGoogle Scholar
- Silvestri L, Pagani A, Camaschella C: Furin mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008, 111: 924-931. 10.1182/blood-2007-07-100677.View ArticlePubMedGoogle Scholar
- Lin L, Nemeth E, Goodnough JB, Thapa DR, Gabayan V, Ganz T: Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis. 2008, 40: 122-131. 10.1016/j.bcmd.2007.06.023.PubMed CentralView ArticlePubMedGoogle Scholar
- Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001, 276: 7806-7810. 10.1074/jbc.M008922200.View ArticlePubMedGoogle Scholar
- Cui Y, Hackenmiller R, Berg L, Jean F, Nakayama T, Thomas G, Christian JL: The activity and signaling range of mature BMP-4 is regulated by sequential cleavage at two sites within the prodomain of the precursor. Genes Dev. 2001, 15: 2797-2802.PubMed CentralPubMedGoogle Scholar
- Kaup M, Dassler K, Weise C, Fuchs H: Shedding of the transferrin receptor is mediated constitutively by an integral membrane metalloprotease sensitive to tumor necrosis factor alpha protease inhibitor-2. J Biol Chem. 2002, 277: 38494-38502. 10.1074/jbc.M203461200.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.